Immuneering Earnings Call Transcripts
Fiscal Year 2026
-
Atebimetinib demonstrated a 64% 12-month overall survival in first-line pancreatic cancer, with robust tolerability and unique mechanisms supporting both efficacy and quality of life. The pivotal phase III trial is set to begin dosing mid-year, with a top-line OS readout expected in about two years.
-
Deep Cyclic Inhibitors, led by atebimetinib, show promising survival and tolerability in First-Line pancreatic cancer, with 64% 12-month survival and minimal added toxicity. A pivotal phase III trial is launching, and combination studies in lung cancer are planned.
-
Atebimetinib, a novel Deep Cyclic Inhibitor, demonstrated 64% 12-month survival in first-line pancreatic cancer, nearly doubling standard benchmarks. A global Phase III trial will begin mid-year, with expanded cohort data expected in 2026, and strong enthusiasm from investigators and KOLs.
-
Atebumetanib plus chemotherapy achieved a 64% 12-month overall survival in first-line pancreatic cancer, nearly doubling the standard of care, with strong durability, favorable safety, and significant quality of life improvements. The upcoming Phase 3 trial will further evaluate these benefits.
Fiscal Year 2025
-
Extraordinary survival and tolerability data were presented for a novel deep cyclic inhibitor in first-line pancreatic cancer, with robust results in an older patient population and plans for a pivotal Phase 3 trial in 2026. Recent financing extends runway into 2029.
-
Exceptional nine-month overall survival of 86% was reported for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer, with strong tolerability and rare complete responses observed. Cash position improved to $227.6 million, funding operations into 2029.
-
A phase II-A trial of atobemetinib plus modified chemotherapy in first-line pancreatic cancer showed a 94% six-month overall survival, 72% progression-free survival, and strong tolerability with minimal serious adverse events. The unique deep cyclic inhibition mechanism supports durable responses and broad potential across cancers.
-
A novel approach using deep cyclic inhibition aims to make cancer a chronic, manageable disease by maximizing durability and tolerability. Early clinical data for IMM-1104 in pancreatic cancer show durable responses, high tolerability, and promising combination results.
-
The session highlighted strong clinical progress for 104, a novel MEK inhibitor, with encouraging efficacy and tolerability in pancreatic cancer, especially in combination with standard chemotherapy. A pivotal study is being planned, with a major data update expected in Q2.
-
IMM-1-104 shows promising efficacy and tolerability in first-line pancreatic cancer, with response rates nearly double standard care and a strong safety profile. Planned phase 3 trials and new collaborations, including with Regeneron, aim to expand its use across multiple cancer types.
-
IMM-1-104 in phase IIA pancreatic cancer arms showed a 43% ORR and 86% DCR in first-line combination, with strong tolerability and no serious drug-related adverse events. Plans are underway for a pivotal phase III trial and further expansion into other cancers.
Fiscal Year 2024
-
The company is advancing a novel deep cyclic inhibition approach targeting the MAP kinase pathway, with early phase IIA data in pancreatic cancer showing rare complete and partial responses and a strong safety profile. Multiple expansion arms are underway, with further data and pipeline updates expected by year-end.
-
Initial Phase II-A data show a 40% response rate and 80% disease control in first-line pancreatic cancer patients treated with IMM-1-104 plus modified chemotherapy, with strong tolerability and a rare complete response observed. All patients remain on treatment, and further updates are planned.
-
IMM-1-104 demonstrated strong tolerability and broad MAP kinase pathway inhibition in phase I, with encouraging early efficacy in late-line pancreatic cancer. Multiple phase II-A arms, including combination therapies, are underway with data expected this year. Cash reserves support operations into H2 2025.
-
IMM-1-104, using Deep Cyclic Inhibition, showed strong safety and promising activity in late-line cancer patients, with no RAS-mediated resistance and notable tumor shrinkage. Phase 2a trials, including combination and monotherapy arms across multiple tumor types, are underway with initial data expected in 2024.